Shanghai Pharmaceuticals' Unit Gets Nod to Trial B019 Injection for Lupus

MT Newswires Live

Jul 30

Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Biotherapeutics, will be able to conduct clinical trials on the B019 injection for an additional condition after obtaining approval from the Chinese drug administration, according to a Shanghai bourse filing on Wednesday.

The drug will be trialed as a treatment for refractory systemic lupus erythematosus.

The drug is also being tested as a treatment for relapsed or refractory acute B-lymphoblastic leukemia and relapsed or refractory B-cell non-Hodgkin's lymphoma, with the approvals being received in October 2023 and December 2024, respectively.

Shanghai Pharma's Hong Kong shares rose over 1% and Shanghai shares jumped more than 2% during morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555099817"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555099817\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555099817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555099817","market":"nz","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Unit Gets Nod to Trial B019 Injection for Lupus","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Biotherapeutics, will be able to conduct clinical trials on the B019 injection for an additional condition after obtaining approval from the Chinese drug administration, according to a Shanghai bourse filing on Wednesday.</p><p>The drug will be trialed as a treatment for refractory systemic lupus erythematosus.</p><p>The drug is also being tested as a treatment for relapsed or refractory acute B-lymphoblastic leukemia and relapsed or refractory B-cell non-Hodgkin's lymphoma, with the approvals being received in October 2023 and December 2024, respectively.</p><p>Shanghai Pharma's <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> shares rose over 1% and Shanghai shares jumped more than 2% during morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Unit Gets Nod to Trial B019 Injection for Lupus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Unit Gets Nod to Trial B019 Injection for Lupus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-30 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Biotherapeutics, will be able to conduct clinical trials on the B019 injection for an additional condition after obtaining approval from the Chinese drug administration, according to a Shanghai bourse filing on Wednesday.</p><p>The drug will be trialed as a treatment for refractory systemic lupus erythematosus.</p><p>The drug is also being tested as a treatment for relapsed or refractory acute B-lymphoblastic leukemia and relapsed or refractory B-cell non-Hodgkin's lymphoma, with the approvals being received in October 2023 and December 2024, respectively.</p><p>Shanghai Pharma's <a href=\"https://laohu8.com/S/HKRHF\">Hong Kong</a> shares rose over 1% and Shanghai shares jumped more than 2% during morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2555099817","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555099817","pubTimestamp":1753845150,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Biotherapeutics, will be able to conduct clinical trials on the B019 injection for an additional condition afte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0012":"证金概念","BK0028":"国家队","BK0097":"医药电商","BK0196":"行业龙头","BK0188":"融资融券","BK1197":"保健护理产品经销商","BK0175":"白马股","BK0209":"零售","BK0187":"一线龙头","BK0184":"上海国资改革","02607":"上海医药","BK0099":"上海本地重组","BK0020":"浦东新区","BK0183":"MSCI概念"},"translate_title":"上海医药旗下B019注射液治疗狼疮试验获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"02607":0.9},"content_text":"Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Biotherapeutics, will be able to conduct clinical trials on the B019 injection for an additional condition after obtaining approval from the Chinese drug administration, according to a Shanghai bourse filing on Wednesday.The drug will be trialed as a treatment for refractory systemic lupus erythematosus.The drug is also being tested as a treatment for relapsed or refractory acute B-lymphoblastic leukemia and relapsed or refractory B-cell non-Hodgkin's lymphoma, with the approvals being received in October 2023 and December 2024, respectively.Shanghai Pharma's Hong Kong shares rose over 1% and Shanghai shares jumped more than 2% during morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}